NCT07151560View on ClinicalTrials.gov

Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2030

Conditions
Urology
Interventions
DRUG

6 cycle RC48 and JS001

Different medication cycles

DRUG

12 cycle RC48 and JS001

Different medication cycles

All Listed Sponsors
lead

Renmin Hospital of Wuhan University

OTHER